Journal of the International Society of Sports Nutrition, 17 (1)
This guidance follows the FDAs approval of Wegovy (semaglutide) for an expanded indication to reduce the risk of major cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in adults with established cardiovascular disease (CVD) and who are either obese or overweight
Diabetes 68 , 906917 (2019)
A Quick Look at the Mechanism GLP-1 receptor agonists can help lower blood sugar and promote weight loss by mimicking a natural hormone that tells your body to release insulin, slow digestion, and reduce appetite
The race is no longer just about scienceits about scale, access, and economics
This dual action, controlling blood sugar and significantly reducing hunger, is why they have become such a powerful tool for both diabetes management and weight loss